These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17446072)

  • 1. Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists.
    Xie YF; Lake K; Ligsay K; Komandla M; Sircar I; Nagarajan G; Li J; Xu K; Parise J; Schneider L; Huang D; Liu J; Dines K; Sakurai N; Barbosa M; Jack R
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3367-72. PubMed ID: 17446072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.
    Revesz L; Bollbuck B; Buhl T; Eder J; Esser R; Feifel R; Heng R; Hiestand P; Jachez-Demange B; Loetscher P; Sparrer H; Schlapbach A; Waelchli R
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5160-4. PubMed ID: 16198561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Core exploration in optimization of chemokine receptor CCR4 antagonists.
    Purandare AV; Wan H; Somerville JE; Burke C; Vaccaro W; Yang X; McIntyre KW; Poss MA
    Bioorg Med Chem Lett; 2007 Feb; 17(3):679-82. PubMed ID: 17098428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists.
    Lai G; Merritt JR; He Z; Feng D; Chao J; Czarniecki MF; Rokosz LL; Stauffer TM; Rindgen D; Taveras AG
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1864-8. PubMed ID: 18304809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclobutane derivatives as potent NK1 selective antagonists.
    Wrobleski ML; Reichard GA; Paliwal S; Shah S; Tsui HC; Duffy RA; Lachowicz JE; Morgan CA; Varty GB; Shih NY
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3859-63. PubMed ID: 16682196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.
    de Dios A; Shih C; López de Uralde B; Sánchez C; del Prado M; Martín Cabrejas LM; Pleite S; Blanco-Urgoiti J; Lorite MJ; Nevill CR; Bonjouklian R; York J; Vieth M; Wang Y; Magnus N; Campbell RM; Anderson BD; McCann DJ; Giera DD; Lee PA; Schultz RM; Li LC; Johnson LM; Wolos JA
    J Med Chem; 2005 Apr; 48(7):2270-3. PubMed ID: 15801819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racemic and chiral lactams as potent, selective and functionally active CCR4 antagonists.
    Newhouse B; Allen S; Fauber B; Anderson AS; Eary CT; Hansen JD; Schiro J; Gaudino JJ; Laird E; Chantry D; Eberhardt C; Burgess LE
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5537-42. PubMed ID: 15482919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
    Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
    J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, structure-activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists.
    Xia M; Hou C; DeMong DE; Pollack SR; Pan M; Brackley JA; Jain N; Gerchak C; Singer M; Malaviya R; Matheis M; Olini G; Cavender D; Wachter M
    J Med Chem; 2007 Nov; 50(23):5561-3. PubMed ID: 17929797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent small molecule CCR1 antagonists.
    Kath JC; Brissette WH; Brown MF; Conklyn M; DiRico AP; Dorff P; Gladue RP; Lillie BM; Lira PD; Mairs EN; Martin WH; McElroy EB; McGlynn MA; Paradis TJ; Poss CS; Stock IA; Tylaska LA; Zheng D
    Bioorg Med Chem Lett; 2004 May; 14(9):2169-73. PubMed ID: 15081002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists.
    Merritt JR; Liu J; Quadros E; Morris ML; Liu R; Zhang R; Jacob B; Postelnek J; Hicks CM; Chen W; Kimble EF; Rogers WL; O'Brien L; White N; Desai H; Bansal S; King G; Ohlmeyer MJ; Appell KC; Webb ML
    J Med Chem; 2009 Mar; 52(5):1295-301. PubMed ID: 19183043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists.
    Merritt JR; Rokosz LL; Nelson KH; Kaiser B; Wang W; Stauffer TM; Ozgur LE; Schilling A; Li G; Baldwin JJ; Taveras AG; Dwyer MP; Chao J
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4107-10. PubMed ID: 16697193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR1 antagonists for the treatment of autoimmune diseases.
    Gladue RP; Zwillich SH; Clucas AT; Brown MF
    Curr Opin Investig Drugs; 2004 May; 5(5):499-504. PubMed ID: 15202722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of 6-benzyl substituted 4-aminocarbonyl-1,4-diazepane-2,5-diones as orally active human chymase inhibitors.
    Maruoka H; Muto T; Tanaka T; Imajo S; Tomimori Y; Fukuda Y; Nakatsuka T
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3435-9. PubMed ID: 17434735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
    Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
    J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP(4) receptor.
    Burch JD; Belley M; Fortin R; Deschênes D; Girard M; Colucci J; Farand J; Therien AG; Mathieu MC; Denis D; Vigneault E; Lévesque JF; Gagné S; Wrona M; Xu D; Clark P; Rowland S; Han Y
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2048-54. PubMed ID: 18291643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.
    Pennell AM; Aggen JB; Sen S; Chen W; Xu Y; Sullivan E; Li L; Greenman K; Charvat T; Hansen D; Dairaghi DJ; Wright JJ; Zhang P
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1228-31. PubMed ID: 23374868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel CCR1 antagonists with improved metabolic stability.
    Brown MF; Avery M; Brissette WH; Chang JH; Colizza K; Conklyn M; DiRico AP; Gladue RP; Kath JC; Krueger SS; Lira PD; Lillie BM; Lundquist GD; Mairs EN; McElroy EB; McGlynn MA; Paradis TJ; Poss CS; Rossulek MI; Shepard RM; Sims J; Strelevitz TJ; Truesdell S; Tylaska LA; Yoon K; Zheng D
    Bioorg Med Chem Lett; 2004 May; 14(9):2175-9. PubMed ID: 15081003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.
    Yu Y; Dwyer MP; Chao J; Aki C; Chao J; Purakkattle B; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Qiu H; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; He Z; Lai G; Wu M; Taveras A
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1318-22. PubMed ID: 18242983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.